Thrombin;La trombina

Minerva Medica

Volumn 91, Issue 5-6, 2000, Pages 105-112

  Camici, M ^a   Sagripanti, A ^a   Di Mitri, R ^a  

^a Dipartimento di Medicina Interna   (Italy)

Author keywords

Thrombin; Thrombin, autogenists and inhibitors

Indexed keywords

ABCIXIMAB; ANTITHROMBIN III; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBIN INHIBITOR;

CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOGENESIS; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ANTITHROMBIN III; BLOOD COAGULATION; COMPARATIVE STUDY; ENGLISH ABSTRACT; FACTOR VIII; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; PLATELET ACTIVATION; RECEPTORS, THROMBIN; RESEARCH; THROMBIN;

EID: 0033783855     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Le recepteur cellulaire de la thrombine
2. A player of many parts: The spotlight falls thrombin's structure
3. Thrombin specificity
4. The refined 1.9. A X-ray crystal structure of D-Phe-Pro-Argchloromethylketoneinhibited human alpha-thrombin: Strucure analysis, overall structure, electrostatic properties, detailed active-site geometry and structure-function relationships
5. Structure and specificity in coagulation and its inhibition
6. The clot thickens: Clues provided by thrombin structure
7. The refined 1.9. A crystal structure of human alpha-thrombin: Interaction with D-Phe-ProArg-chloromethylketone and significance of the TyrPro-Pro-Trp inserction segment
8. Physical evidence of an apolar binding site near the catalytic center of human alpha thrombin
9. Electrostatic intercations in proteins: Calculations of the electrostatic term of free energy and the electrostatic potential field
10. Molecular interactions of thrombin
11. Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibitor
12. Identification of basic aminoacid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III
13. Role of thrombin exosites in inhibition by heparin cofactor II
14. Equilibrium binding of thrombin to recombinant human thrmbomodulin: Effect of hirudin fibrinogen, factor Va and peptide analogues
15. Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets
16. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
17. Trafficking thrombin receptors. Biodiversity on the receptor superhighway
18. La thrombine: Molecule multifonctionelle
19. Platelet procoagulant activity: Physiological significance and mechanism of exposure
20. Syndromes of thrombosis and hypercoagulability: Congenital and acquired causes of thrombosis
21. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
22. C-DNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca mobilization
23. Protease-activated G protein coupled receptors on human platelets and endothelial cells
24. Protease activated receptor 3 is a second thrombin receptor in humans
25. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
26. Thrombin induced expression of endothelial P-selectin and intercellular adhesion molecule-1: A mechanism for stabilizing neutrophil adhesion
27. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolitically activated receptor
28. The thrombin receptor in the nervous system
29. Thrombin and vascular smooth muscle cells proliferation: Implications for atheroscle rosis and restenosis
30. Issues in the development of thrombin receptor antagonists
31. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation
32. Trafficking thrombin receptors. Biodiversity on the receptor superhighway
33. Syndromes of thrombosis and hypercoagulability: Congenital and acquired causes of thrombosis
34. Serpin structures
35. Conformational changes accompanying the binding of antithrombin III to thrombin Biochemistry
36. General features of the heparin binding serpins, antithrombin, heparin cofactor II and protein C inhibitor
37. Thrombin regulation by physiological inhibitors: The role of vitronectin
38. Heparin
39. Heparin binding and neutralizing proteins
40. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
41. Unfractionated and low molecular weight heparin. Comparisons and current recommendations
42. Structure of the antithrombin-binding site of heparin
43. Extension and structural variability of the antithrombin-binding sequence of heparin
44. The structure of heparin oligosaccharide fragments with high anti-factor Xa activity containing the minimal antithrombin III binding sequence
45. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin
46. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight hepa rin fractions: The influence of the method of preparation
47. Low molecular weight heparin. An intringuing new twist with profound implications
48. Hirudin and derivatives as anticoagulant agents
49. Cloning and expression of cDNA coding for the anticoagulant hirudin from the blood su cking leech Hitudo Medicinalis
50. The structure of a complex of recombinant hirudin and human alpha trhombin
51. Anticoagulant activity of synthetic hirudin fragments
52. Design an characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
53. Selective inhibition of thrombin by (2R, 4R)-4-Methyl-1(N-3-methyl-1,2,3,4-tetrahydro-8-quinolynil)-L-argynil)-2-piper idinecarboxylic acid
54. Thrombin interaction
55. 4
56. Peptide aldheyde inhibitors of the fibrinogen-thrombin reaction
57. Thrombin interaction with platelet membrane glicoprotein Ib
58. Structure-function relationship in the activation of platelet thrombin by receptorderived peptides
59. Cloned thrombin receptor is necessary for thrombin induced platelet activation
60. Thrombin mediation of arterial smooth muscle cell (SMC) proliferation after mechanica vascular injury in non human primates
61. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
62. Antistasin, a lecch-derived inhibitor of factor Xa: Kinetic analysis of enzyme inhibitionand identification of the reactive site
63. Characterization of recombinant tick anticoagulant peptide
64. Purification and characterization of recombinant antistasin: A leech derived inhibitor col coagulation Xa
65. The lipoprotein associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
66. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein associated coagulation inhibitor
67. The roles of protein C and thrombomodulin in the regulation of blood coagulation
68. Antithrombotic efficacy and hemostatic safety of activated protein C in vivo
69. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates
70. Hirudin in acute mycardial infarction: Safety report from the thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
71. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
72. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation
73. Safety observations from the pilot phase of the randomized r-hirudin for Improvement of Thrombolysis (HIT-tII) Study
74. Direct thrombin inhibition and thrombolytic therapy: Rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial
75. Evolution of improved antithrombotic and antiplatelet agents: Genesis of the Comparison of Abciximab Complications with Hirulog (and back-up abciximab) Events Trials (CACHET)
76. Intravenous argatraban versus heparin as comedication to alteplase in the treatment of acute myocardial infarction: Preliminary results of the ARGAMI pilot study
77. Pilot study of argatraban in patients with heparin allergy